Spyre Therapeutics, Inc.SYRENASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
75.00%
↑ 347% above average
Average (39q)
-30.36%
Historical baseline
Range
High:88.97%
Low:-1061.35%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 75.00% |
| Q2 2025 | -361.54% |
| Q1 2025 | 13.33% |
| Q4 2024 | 88.97% |
| Q3 2024 | -58.14% |
| Q2 2024 | 28.33% |
| Q1 2024 | 58.76% |
| Q4 2023 | 68.84% |
| Q3 2023 | 83.55% |
| Q2 2023 | -1061.35% |
| Q1 2023 | 32.08% |
| Q4 2022 | -48.76% |
| Q3 2022 | 28.72% |
| Q2 2022 | 26.67% |
| Q1 2022 | 10.62% |
| Q4 2021 | -34.20% |
| Q3 2021 | -196.92% |
| Q2 2021 | 62.54% |
| Q1 2021 | 29.33% |
| Q4 2020 | -35.64% |
| Q3 2020 | 28.39% |
| Q2 2020 | 28.55% |
| Q1 2020 | 14.35% |
| Q4 2019 | -0.73% |
| Q3 2019 | -19.53% |
| Q2 2019 | 7.23% |
| Q1 2019 | 1.07% |
| Q4 2018 | -10.33% |
| Q3 2018 | -18.55% |
| Q2 2018 | 6.08% |
| Q1 2018 | -19.43% |
| Q4 2017 | 15.08% |
| Q3 2017 | -2.13% |
| Q2 2017 | -0.60% |
| Q1 2017 | 1.35% |
| Q4 2016 | -1.20% |
| Q3 2016 | -1.47% |
| Q2 2016 | -15.88% |
| Q1 2016 | -14.11% |
| Q4 2015 | -22.64% |